# NMSC Immunotherapy Guide IAR

> NMSC Immunotherapy Guide IAR (iPhone/iPad app by UMA MLG, LLC.)

- Source: https://appshunter.io/ios/app/nmsc-immunotherapy-guide-iar/id6771424147 (this page in markdown: same URL + `.md`)
- Developer: [UMA MLG, LLC](https://appshunter.io/developer/1268829636)
- Category: Medical
- Price: Free
- Age rating: 17+
- Requires: iOS 13.0 · 465 MB
- Languages: English
- Released: 2026-05-28
- Data updated: 2026-06-16
- User reviews in markdown: https://appshunter.io/ios/app/nmsc-immunotherapy-guide-iar/id6771424147/reviews.md

## What is NMSC Immunotherapy Guide IAR?

In nonmelanoma skin cancer (NMSC), particularly cutaneous squamous cell carcinoma (cSCC), treatment selection has evolved with the integration of immune checkpoint inhibitors (ICIs) across multiple stages of disease. Current guidelines support a risk-adapted approach in which ICIs play a central role for patients with high-risk, locally advanced, or metastatic disease, as well as an emerging role in earlier treatment settings.

For unresectable or metastatic disease, ICIs targeting the PD-1/PD-L1 pathway are the preferred systemic therapy, offering durable responses and a favorable tolerability profile compared with traditional approaches. Their use is supported by the underlying tumor biology of cSCC, which is characterized by a high tumor mutational burden driven by ultraviolet radiation exposure. This leads to increased neoantigen formation and enhanced tumor immunogenicity, making these tumors particularly responsive to immune modulation. In addition, upregulation of immune checkpoint pathways such as PD-1/PD-L1 contributes to immune evasion, providing a strong mechanistic rationale for checkpoint blockade.

Beyond advanced disease, ICIs are increasingly being incorporated into neoadjuvant and adjuvant treatment strategies for high-risk, resectable NMSC. In the neoadjuvant setting, ICIs may reduce tumor burden, improve surgical outcomes, and, in some cases, enable less extensive resections. In the adjuvant setting, they are being explored to reduce the risk of recurrence following surgery, particularly in patients with high-risk pathologic features. These approaches reflect a shift toward earlier immune intervention in the disease course.


## Version history (last 1 release)

### 1.0 — 2026-05-28

No release notes.

## More apps by UMA MLG, LLC

- [Diabetes MOA Augmented Reality](https://appshunter.io/ios/app/diabetes-moa-augmented-reality/id1288349084)
- [CV Augmented Reality](https://appshunter.io/ios/app/cv-augmented-reality/id1398041008)
- [EMPOWER Breast AR](https://appshunter.io/ios/app/empower-breast-ar/id1449170577)
- [Diabetic Retinopathy AR](https://appshunter.io/ios/app/diabetic-retinopathy-ar/id1467432393)
- [SGLT2 & GLP-1 in Diabetes](https://appshunter.io/ios/app/sglt2-and-glp-1-in-diabetes/id1480885616)
- [AMD & Anti-VEGF Therapy](https://appshunter.io/ios/app/amd-and-anti-vegf-therapy/id1511601192)

All apps by UMA MLG, LLC: https://appshunter.io/developer/1268829636

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-06-16.*